Monopar resurrects a shelved Wilson disease drug. Spotting a possible math problem helped

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Monopar Therapeutics has resurrected a promising treatment for a rare condition called Wilson disease after discovering that AstraZeneca, the drug’s former owner, terminated clinical development due to an inadvertent error made in a clinical trial. 

If approved, possibly in the latter half of 2026, the drug, called ALXN1840, would be the first novel treatment for Wilson disease in 40 years. Monopar acquired the shelved drug from AstraZeneca one year ago, and plans to submit for U.S. approval early next year. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In